On February 15, 2022 Evotec SE (FSE: EVT; MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) reported that has made an equity investment in IMIDomics, Inc., a privately held global biotechnology company focused on the discovery and development of new targets and medicines for the treatment of patients with immune-mediated inflammatory diseases ("IMIDs") (Press release, Evotec, FEB 15, 2022, View Source [SID1234608174]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

IMIDs affect nearly one in ten people – limiting quality of life and creating significant challenges to physical and mental well-being. The complexity of these diseases means even getting a diagnosis can be a long-term struggle for patients, and then finding a treatment that works can be a frustrating, time-consuming trial and error process.

"Evotec and IMIDomics are perfectly aligned on their goal to leverage data to discover and develop precise-acting, effective medicines of the future," said Dr Werner Lanthaler, Chief Executive Officer of Evotec. "By joining IMIDomics as a minority shareholder, we are excited to further grow our EVOequity portfolio of highly promising companies with complementary technologies and assets."

In conjunction with the investment, an Evotec representative will join the IMIDomics board of directors. No financial details were disclosed.